- CSR Summary Not yet available
- NCT02905331
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaImmune System DiseasesEnrollment78% Female32.1%% WhiteN/A
Product ClassmAB anti-IL12 and anti-IL23Sponsor Protocol NumberCNTO1959PSO3006Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)46
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available